– DENMARK, Copenhagen – Orbis Medicines, a leader in oral macrocycle drug discovery, announced the appointment of Dr. Mikael Dolsten ( M.D., Ph.D.) as Chair of its Board of Directors.
About Dr. Mikael Dolsten
In more than 15 years at Pfizer, Dr. Mikael Dolsten oversaw the development and approval of more than 35 therapies and vaccines and moved more than 100 drug candidates into clinical development. Before his tenure at Pfizer, he served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals. Dr. Mikael Dolsten has served on several public boards in the US and Europe and has vast experience in business development, including 10 different mergers and acquisitions.
“By creating oral alternatives to biologics such as antibodies and peptides and designing oral drugs for hard-to-drug intracellular targets, the work Orbis Medicines is doing will dramatically expand access to treatment for patients suffering from many chronic and devastating diseases, which is truly the next frontier in drug discovery,” said Dr. Mikael Dolsten. “What the Orbis Medicines team led by Morten are achieving in the field of oral macrocycle medicines positions the company to be a disruptor of the biologics market. I believe Orbis Medicines has the potential to become the leading oral macrocycles and oral biologics biotech company.”
His accomplishments include the introduction of a new class of oral medications for autoimmune diseases, the development and approval of targeted anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer, and Pfizer’s rapid R&D response to the COVID-19 pandemic.
About Orbis Medicines
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered the therapeutic development of this versatile class of molecules. Orbis’ pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis’ work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO, and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark, and Lausanne, Switzerland.
For more information, www.orbismedicines.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.